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A b s t r a c t  
The present study investigated the effect of spray drying raloxifene HCl (RHCL) with different 
classes of hydrophilic carriers (different grades of polyvinyl pyrrolidones) and cellulosic polymers) in 
order to determine the potential effect on dissolution rate and bioavailability of RHCL. Pre-
formulation studies were conducted to select the appropriate carriers and drug:carrier ratio for 
preparing the spray dried compositions.The solid state interactions of the spray dried mixtures were 
evaluated by DSC & XRD. Preformulation studies revealed that amorphous compositions of RHCL 
could be obtained only with Plasdones (K12, K29/32 and S630). DSC studies showed that the 
crystalline nature of RHCL was significantly reduced on spray drying. Significant enhancement in 
dissolution rate was observed with the prepared spray dried compositions and out of the three 
grades of Plasdone, Plasdone K12 demonstrated the maximum enhancement in rate of release of 
RHCL. The pharmacokinetics of spray dried composition (1:1 RHCL: K12) and pure RHCL was 
evaluated following oral administration (25 mg/kg) in healthy female Sprague Dawley rats. The 
extent of the mean plasma exposures of RHCL was 7-fold higher in animals treated with spray dried 
mixture of RHCL, K12 (1:1) compared to animals treated with RHCL. Spray drying of RHCL with 
Plasdones, especially Plasdone K12, reduced drug crystallinity, increased the rate and extent of 
dissolution, and improved bioavailability.. 
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Introduction  
Raloxifene hydrochloride (RHCL) is a selective estrogen receptor 
modulator (SERM) shown to be effective in the prevention of 
osteoporosis, with potential utility as a substitute for long-term 
female hormone replacement therapy [1-3].  However, it is a drug 
with low water solubility and high membrane permeability included 
in class II of Biopharmaceutical drug classification system. It has 
an absolute bioavailability of approximately 2% in humans and its 
bioavailability could consequently be increased by improving its 
solubility [4] 
Poorly soluble drugs may benefit from formulation approaches that 
overcome poor solubility and dissolution rate limited bioavailability. 
The solubility of a compound in the amorphous form is higher than 
in the more stable crystalline form because the Gibb’s free energy 
is higher [5]. The dissolution rate of an amorphous compound is 
improved relative to the crystalline form and it can be further 
improved if the amorphous compound is dispersed in a hydrophilic 
polymer [6]. 
Solubility can be enhanced by using several methods. Techniques 
such as micronization [7,8], co-grinding [9-11], solid dispersions 
[12], complexation, spray drying, super critical fluid technology and 
lipid –based drug delivery system have commonly been used to 
improve the dissolution and bioavailability of poorly water soluble 
drugs. 
Spray drying is a particle processing technology that transforms a 
liquid feedstock into a powder product by first spraying the 
feedstock to create droplets, and then evaporating the feedstock 
liquid through the use of a heated drying medium, typically air. The 
liquid feedstock can take the form of a solution, suspension, liquid-
paste, or emulsion, and must be pumpable and capable of droplet 
formation [13]. Spray drying has gained more importance as a 
method of microencapsulation. This method has already been used 
to prepare micro particles with polyesters, polymethacrylates, 
cellulose derivatives and biopolymers containing both hydrophilic 
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and lipophilic drugs and macromolecules. Compared with other 
techniques, like solvent evaporation, it has many advantages, 
including shorter duration, reliability and reproducibility, cost 
effectiveness of process preparation, particle size control, good 
yield of production and the possibility of being free of organic 
solvent [14,15]. Examples of successfully tested drugs which 
improved their dissolution by spray drying technique are 
indomethacin [16], tolbutamide [17], carbamazepine [18], 
ketoprofen [19] and Albendazole [20].  
In an earlier study [4],  we had investigated the effect of co-grinding 
of RHCL with different hydrophilic carriers such as PVP, HPMC, 
HPC and sodium alginate and found that significant enhancement 
in dissolution of RHCL was observed with co-ground mixtures of 
PVPs. The aim of the present study was to investigate the 
feasibility of improving the rate of dissolution and bioavailability of 
RHCL using hydrophilic polymers like PVP (different grades), 
Hydroxy propyl cellulose (HPC), hydroxypropyl methyl cellulose 
(HPMC) and Hydroxypropyl methyl cellulose Acetate succinate 
(HPMC AS). 
Experimental 
Materials 
Raloxifene (Glochem Industries Ltd., Hyderabad, India) was 
purchased from the source indicated. HPMC (Pharmacoat 603), 
Hydroxypropyl cellulose (HPC, Klucel EF) and Hydroxypropyl 
methyl cellulose acetate succinate (HPMC AS, LF, MF and HF) 
were purchased from Signet (Mumbai, India). Polyvinyl 
pyrrolidones (Plasdone K12, K29/32 and S-630) were in-house 
materials (International Specialty Products, New Jersey, US). All 
other reagents used were of analytical grade. 
Solubility of Raloxifene 
The solubility of RHCL in various solvents and in solvent mixtures 
was determined using a gravimetric method. 10 ml of the various 
solvents and the solvent mixture were taken in a stoppered glass 
bottle, to which accurately weighed graded amount of the drug was 
added and after each addition the bottles were shaken using a 
shaker. Addition of drug was stopped, when no further drug goes 
into solution and the bottles were shaken for a period of 24 hours. 
The point where no further drug goes into solution was taken as 
the ‘saturation point’ for that particular solvent and the weight of the 
drug added up to that point was considered for calculating the 
solubility in that particular solvent system. 
Film studies of Raloxifene with polymers 
Film studies were carried out with different drug: polymer ratios 
(1:1, 1:3 and 3:1). Polymers used include Plasdone K12, K 29 and 
S 630, HPMC (Pharmacoat 603 and 606), HPC (Klucel EF), HPMC 
acetate succinate (HPMC AS – LF, MF, HF). The drug polymer 
mixtures were dissolved in a mixture of methanol and DMF. The 
solution was then poured on glass slides using a dropper and 
allowed to dry under vacuum for 3 hours at 60°C. The dried films 
were then subjected to DSC at a heating rate of 10°C / min. 
Preparation of RHCL spray-dried compositions  
Polymeric solution of the different PVP grades (Plasdone K12, 
K29/32 and S630) was prepared by dissolving the polymer in 
methanol (0.5 or 1.5% w/v according to the ratio desired). RHCL 
was dissolved in dimethyl foramamide (DMF) (0.5% w/v) and the 
solution of the drug was added to the polymeric solution. The 
prepared drug/polymer solution, in the desired ratio, was spray 
dried using Buchi (B-290, Flawil, Switzerland) with 0.5 mm nozzle. 
The RHCL:PVP solutions were fed to the nozzle via peristaltic 
pump (flow rate of 8 ml/min). The volume of solution sprayed was 
200 ml. The solutions were sprayed as atomized droplets by the 
force of compressed nitrogen (nitrogen flow rate of 42 kg/cm2). The 
solvents in the droplets were evaporated in the drying chamber by 
the blown hot nitrogen (inlet nitrogen temperature of 180°C and 
outlet nitrogen temperature of 120°C). The dried products were 
collected in the collection vessel and weighed. 
Assay of spray-dried compositions (HPLC) 
RHCL content in the spray dried compositions were performed with 
HPLC (Waters, Milford,USA) using 5-µm, 250 X 4.6mm i.d Inertsil 
C8 column (GL Sciences Inc., Japan) by a gradient elution method 
reported earlier (Kerry et al. 2000). The gradient elution utilized 
acetonitrile and a 75 mM phosphate buffer adjusted to pH 3.0 with 
85% phosphoric acid. The initial mobile phase composition of 25% 
acetonitrile was maintained for 5 min, and then increased by 
0.8%/min to final composition of 50% acetonitrile.  RHCL was 
monitored using a UV detector at a wave length of 280 nm.  
Estimation of Methanol and DMF in spray dried 
compositions using HSS-GC 
Organic volatile impurities (methanol and DMF) were estimated 
using headspace Gas chromatography (Agilent 6890N) using 
capillary column DB-624 30 meters, 530 µm internal diameter and 
3µm film thickness. The initial oven temperature was held at 40°C 
for 20 minutes and increased at the rate of 10°C per minute up to 
240°C and held for further 20 minutes. Injector and detector 
temperatures were maintained at 140 and 250°C, respectively and 
column flow was maintained 4.9 ml/minute.  
Differential Scanning Calorimetry 
Thermal curves of each spray fried sample was recorded by 
simultaneous Differential Scanning Calorimeter (TA Instruments Q 
1000, Bangalore, India). Each Sample (~ 2-3 mg) was scanned in 
aluminum pan at a heating rate of 10C/min over the range of 50-
3000C with an empty aluminum pan used as reference. Samples 
were heated under nitrogen atmosphere (flow rate of N2- 
50mL/min). 
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X-Ray Diffraction (XRD) 
Powder XRD patterns were traced employing X-ray diffractometer 
(Model No. 3000, Seifert, Germany) for the samples, using Ni-
filtered Cu-K radiation, a voltage of 40kV, a current of 30mA 
radiation scattered in the crystalline regions of the sample, which 
was measured with a vertical goniometer. Patterns were obtained 
by using a step width of 0.04°C with a detector resolution in 
2q(diffraction angle) between 10° and 80° at ambient temperature. 
FT-IR Spectroscopy 
FT-IR spectra were obtained using FT-IR spectrometer (Nicolet 
5700, Thermo Scientific, Madison, WI, USA) by the conventional 
KBr pellet method. The samples were ground gently with 
anhydrous KBr and compressed to form pellet. The scanning range 
was 400-4000 cm-1 and the resolution was 4 cm-1. 
In-Vitro Dissolution Studies 
In-Vitro  dissolution testing employed the United States 
Pharmacopeia (USP) Apparatus II (VK 7010 Varian, Cary, NC, 
USA) at 50 rpm with 1000 mL of water with 0.1% Tween 80 at 37 ± 
0.50C. Six capsules of each batch containing powder sample 
equivalent to 50mg RHCL were tested. The sample of the 
dissolution media was removed using an automated sampling 
system at a predetermined time interval (0, 5, 10, 15, 30, 45 and 60 
min) and was simultaneously analyzed spectrophotometrically at 
λmax of 285nm (Cary 50 UV- Spectrophotometer attached with 
dissolution Apparatus; Cary, NC, USA). The time required for 80% 
of drug to be released (T80%) was considered for comparing the 
dissolution results. The T30% was determined by fitting the 
dissolution data to a four parametric logistic model using the 
Marquardt-Levenberg algorithm (Sigmaplot 9.0 SPSS Inc., 
Chicago, IL) [20].  
Y=min+max-min / 1+10 [log ec50-x]x hillslope 
In this equation, y, represents the cumulative % drug released; x, 
the time in min; min, the baseline of % drug released at time 0 
minute; max, the plateau of % drug released at time 60 minutes 
and hill slope, the slope of the curve at transition center EC50. 
Pharmacokinetic study in rats 
The study was conducted at Advinus Therapeutics Pvt. Ltd., 
Bangalore, India after getting the Ethical Committee Approval. In 
total 12 (6 per group) female Sprague Dawley rats (6-7 weeks old) 
weighing between 180-230 g were used for the study. All rats had 
free access to tap water and pelleted diet (Ssniff rats pellet food, 
Ssniff Spezialdiaten, Germany). The rats were housed in a cage 
and maintained on a 12h light/dark at room temperature (210C to 
240C) and relative humidity of 50 to 70% and acclimatized to study 
area conditions for atleast 5 days before dosing. General and 
environmental conditions were strictly monitored. The room 
underwent 10 fresh air change cycles per hour. Rats were 
implanted with canula in the jugular vein for blood sampling. The 
surgery was performed two days before dosing under anesthesia. 
The animals were fasted at least 10 h prior to dose administration 
and for 4 hours post dose with free access to water. Individual oral 
doses of the test and reference samples were prepared (25mg/kg 
free base) and accurately weighed drug material was carefully 
transferred into the dosing syringe containing aliquot of gelatin gel.  
Transfer the sample into the syringe barrel was accomplished 
either using a butter-paper funnel/with a spatula; the funnel was 
weighed before and after transferring drug to account for any loss 
by sticking to funnel. Separate funnels were used to prepare each 
dose. After transfer of the drug material into the syringe, an aliquot 
of gelatin was placed on top of the drug powder, thus effectively 
sandwiching it between 2 layers of gelatin. The sample was 
attached to an oral feeding needle and administered into the 
stomach. After dosing, syringe was rinsed with 1mL of water and 
dosed again. Serial blood samples (250µL) were withdrawn from 
the cannulated jugular vein at: Pre dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 
12 and 24 h post-dosing and collected in labeled tubes containing 
20 µL of EDTA dipotassium dehydrate solution (200mM) per ml of 
blood as anticoagulant. Blood samples were held on ice until 
centrifuged at 10000 rpm; 40C for 10min. Plasma was transferred 
to individual Eppendorf tubes and stored below -700C until 
bioanalysis. 
Bioanalysis 
The samples were analyzed by combined reversed phase liquid 
chromatography tandem mass spectrometry (LC-MS/MS Model no: 
API 4000, Applied Biosystems, Foster city, USA) by multiple 
reaction monitoring (MRM) and Positive ionization mode. The 
samples were prepared for analysis by liquid – liquid extraction 
using a TBME. Chromatography was performed on a 150mm X 
4.6mm Kromasil C18 Column (Thermo) using isocratic elution with 
80:20 methanol and aqueous 10mM ammonium acetate (pH 5.0). 
Raloxifene pure drug was used as the internal standard. Under 
these conditions, no interference was observed for both samples 
and pure drug. The standard curve was linear from 1ng/ml to 2000 
mg/ml.  
Pharmacokinetic data analysis 
The area under the drug concentration-time curve from zero to 24 
h (AUC 0→24h) and mean residence time (MRT) were calculated 
using noncompartmental analysis (WinNonlin 2.1, Pharsight Corp., 
Mountain View, CA). The maximal plasma concentration of drug 
(Cmax) and the time to reach maximum plasma concentration 
(Tmax) were directly obtained from plasma data. One-way ANOVA 
and Bonferroni’s multiple pair comparison tests. The differences in 
Tmax among the groups were tested by Kruskal-wallis test and 
Dunn’s multiple pair comparison tests.  
Results and Discussion 
Pre-formulation studies 
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The solubility of RHCL in various solvents was determined so as to 
select an appropriate solvent or solvent system for dissolving both 
the drug and the polymer and is shown in Table 1. Out of the 
solvent studied, both Dimethyl formamide (DMF) and Dimethyl 
sulfoxide (DMSO) were found to be suitable for dissolving RHCL. 
Film studies with various carriers at different drug to carrier ratios 
were done in order to screen for polymers that could convert the 
drug into a less crystalline or an amorphous form. The results of 
the film studies are summarized in Table 2. Out of the polymers 
screened PVP (Plasdone) K12, K29/32 (in ratio of 1:1) and S630 
(ratio of 1:3) converted the drug to the amorphous form (DSC 
thermograms not shown). 
Spray dried compositions  
The prepared spray dried compositions were evaluated for their 
volatile content since a combination of methanol and DMF was 
used as the solvent system for spray drying, by a head space GC. 
Methanol was selected as one of the solvent because of the 
soluble nature of all the polymers, used in the study, in it and out of 
DMF and DMSO, DMF was preferred because of its relatively 
lower boiling point than DMSO. The methanol and DMF eluted at 
2.8 and 27.5 minutes, respectively, owing to their obvious 
difference in their boiling points. The amount of the respective 
solvents, present in the spray dried compositions, were calculated 
relative to the area count of their respective standards (3000 µg/ml 
of pure methanol and 880 µg/ml of DMF, as recommended by ICH 
guidelines). The level of methanol in the spray dried compositions 
was in the range of 475 to 512 µg/ml of methanol and the level of 
DMF was in the range of 60 to 75µg/ml. A representative 
chromatogram is shown in Figure 1. This suggests that spray dried 
compositions contained very less amounts of both the solvents 
since it is significantly lower than the ICH recommended levels. 
This low level of solvent present in the spray dried compositions 
could also aid in lowering of the re-crystallization rate of the drug 
from the spray dried compositions. The spray dried compositions 
had drug content of 98.0 to 102.0% of RHCL, suggesting that the 
spray drying process was successful in achieving good 
encapsulation of the drug. 
DSC of spray dried compositions 
DSC studies were performed on the individual components and on 
the freshly prepared spray dried mixtures in order to study the 
interaction between RHCL and the carriers in the solid state 
(Figure 2). RHCL exhibited a single sharp melting endothermic 
peak at 2670C. The DSC thermograms of different Plasdone 
grades showed a broad endothermic peak in the range of 50-
1300C, which may be attributed to the endothermic relaxation [4]. 
The DSC thermograms further indicated that all the carriers are 
amorphous and hydrated compounds. The thermograms of the 
spray dried compositions containing Plasdone K12 and K29/32 
showed the absence of the characteristic melting endothermic 
peak of RHCL, suggesting the amorphous nature of RHCL in these 
compositions. 
However, a slight shift of the endothermic melting peak and 
broadening was observed in thermogram of the spray dried mixture 
prepared using Plasdone S 630. This suggests that the crystalline 
nature of the drug was greatly reduced by Plasdone S630. 
X-Ray Diffraction (XRD) 
XRD studies were undertaken to consolidate the DSC data 
indicating the reduction of the crystallinity of RHCL with 
Crospovidone. Therefore, the XRD patterns of RHCL, Plasdone 
K12 and the spray dried mixture with drug and Palsdone K12 were 
observed. The diffraction spectrum of RHCL showed that the drug 
was crystalline in nature, as demonstrated by numerous distinct 
peaks observed at 2q of 13.4, 14.4, 15.7, 19.0, 20.9, 21.1, 22.6 
and 25.9 (Figure 3A). XRD pattern of Plasdone K12 and the spray 
dried composition showed no sharp peaks, indicating its 
amorphous nature (Figures 3 B and C). 
Further, no new peaks could be observed, suggesting the absence 
of interaction between the drug and the carrier [12, 22, 23]. This 
suggests that the crystal quality of RHCL is reduced in the spray 
dried mixture [24-26]. These results are similar to DSC results.  
FT-IR Spectroscopy 
FT-IR studies showed that there was no significant changes in the 
spectrum of spray dried mixture with Plasdone K12 when 
compared with drug alone. The absence of shifts in the wave 
numbers of the FT-IR peaks (Figure 4) of the spray dried mixture 
indicates the lack of significant interaction between the drug and 
the carrier in the mixture [25,26]. 
Thus these results ratify the absence of any well-defined 
interaction between RHCL and the grade of Plasdone used. 
Table 1. Solubility of raloxifene in different solvents 
Solvent Solubility(mg/ml) 
Dichloromethane (DCM) < 5 
Ethyl Acetate < 5 
Acetone < 5 
n-Butanol < 5 
Methanol 5 
n-Hexane < 5 
Cyclohexane < 5 
Acetonitrile < 5 
n-Heptane < 5 
Ethylene Chloride < 5 
Ethanol < 5 
Water < 5 
n-Propanol < 5 
IPA < 5 
DMF 260 
DMSO 715 
DMF + Methanol 110 
DMF + DCM 10 
DMF + Acetone 10 
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In vitro release studies 
Table 3 shows the T80% of RHCL, and the different spray dried 
compositions and Figure 5 shows the dissolution profile of pure 
RHCL and the different spray dried compositions. 
The dissolution of RHCL increased significantly (t-test; P<0.05) 
from all the spray dried compositions. Amorphous forms of 
pharmaceuticals are markedly more soluble than their crystalline 
counterparts [27] and improve the dissolution rate [9,12]. Out of the 
three grades of PVP, Plasdone K12 gave the maximum 
enhancement in rate of drug release as evidenced by the T80 
values. This could be due to the relative lower molecular weight of 
Plasdone K12. 
Pharmacokinetic study 
The pharmacokinetic parameters of RHCL were determined after 
oral administration of RHCL and spray dried mixture of RHCL with 
Plasdone K12 in the ratio of 1:1. It was selected on the basis of in-
vitro dissolution studies as discussed above. The plasma 
concentration time data of RHCL are shown in Figure 6 and their 
mean pharmacokinetic parameters are shown in Table 4. 
 
 
Table 2. Film studies of Raloxifene with different Polymers 
Drug: Polymer Ratios 
1:1 1:3 3:1 
RAL:K29 Amorphous Amorphous Amorphous 
RAL:K12 Amorphous Amorphous Endothermic transition at 
225.35 deg C 
RAL: S 630 Endothermic transition at 
245.80 deg C 
Amorphous Endothermic transition at 
252 deg C 
RAL:HPMC  Endothermic transition at 
252.87 deg C 
Endothermic transition at 
260.88 deg C 
Endothermic transition at 
258.54 deg 
RAL:HPC Endothermic transition at 
255.07 deg C 
Endothermic transition at 
254.98 deg C 
Endothermic transition at 
261.77 deg C 
RAL:HPMC AS LF Endothermic transition at 
257.35 deg C 
Endothermic transition at 
252.55 deg C 
Endothermic transition at 
261.44 deg C 
RAL:HPMC AS MF Endothermic transition at 
257.22 deg C 
Endothermic transition at 
252.90 deg C 
Endothermic transition at 
263.06 deg C 
RAL:HPMC AS HF Endothermic transition at 
261.02 deg C 
Endothermic transition at 
257.20 deg C 
Endothermic transition at 
278.16 deg C 
 
Table 3. T80% data of Spray dried compositions of raloxifene 
Sample T80% 
RHCL Not achieved 
RHCL: K12 1:1 22.32 
RHCL: K29 1:1 35.94 
RHCL: S630 1:3 35.24 
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Table 4. Pharmacokinetic parameters of raloxifene with 90% confidence intervals (CI) in female Sprague Dawley rats following oral 
administration of co ground mixture and Raloxifene Pure drug in 1% gelatin gel sandwich (Dose: 25 mg/kg free base) 
 
Sample Tmax (h) Cmax ng/mL) 
AUC0-last 
(ng.h/mL) 
AUC0-inf  
ng.h/mL) MRT0-t T1/2 (h) 
R HCl : K12 1: 1 4 (2.0 -12.0) 116 ± 44.6 931 ± 72.2 1006 ± 66.6 7.9 ± 2.0 4.5 ± 1.9 
RHCL 8 (4.0 - 8.0) 16.9 ± 7.30 138 ± 26.7 184 ± 13.5 9.8 ± 2.1 8.8 ± 2.8 
 
 
 
Figure 1. Representative GC chromatogram of RHCL spray dried mixture showing elution of methanol and DMF 
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Figure 2. DSC of RHCL, Plasdone grades and Spray dried compositions 
 
 
Figure 3.XRD Spectra of (A) RHCL; (B) PVP K12; (C) Spray dried RHCL : K12 1:1 
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Figure 4. FTIR spectra of (A) RHCL; (B) PVP K12; (C) Spray dried RHCL : K12 1:1 
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Figure 5. Dissolution of spray dried RHCL compositions in 1000 ml water 
RHCL 
.  
Figure 6. Pharmacokinetic evaluation of RHCL & RHCL:K-12 spray dried mixture in female Spargue Dawley rats 
following oral administration 
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The extent of the mean plasma exposures of raloxifene was 7 fold 
higher in animals treated with spray dried RHCL compared to 
animals treated with pure RHCL. Thus, the mean Plasma AUC0-last 
in animals that received the spray dried RHCL and pure RHCL was 
931 ± 72.2 ng.h/mL and 138 ± 26.7 ng.h/mL respectively, and they 
were significantly different (p = 0.0001 by ANOVA). Bonferroni’s 
multiple pair comparison tests also showed significant increase 
with spray dried RHCL with Plasdone K12 as compared to RHCL.  
The corresponding mean Cmax values for these treatment groups 
were 116 ± 44.6 ng/ml, and 16.9 ± 7.3 ng/ml and these were 
significantly different (p = 0.0052 by ANOVA). Bonferroni’s multiple 
pair comparison tests showed significant increase with the spray 
dried composition compared to RHCL. 
Conclusion 
In the conclusion, the spray dried form of raloxifene HCl with 
Plasdone K12 in a ratio of 1:1 reduced drug crystallinity, increased 
the rate and extent of dissolution significantly than that of pure drug 
which might be due to the nano size of dispersion. The 
pharmacokinetics of spray dried composition (1:1 RHCL: K12) by 
following oral administration was evaluated in rats. The results 
revealed that extent of the mean plasma exposures of RHCL was 
7-fold higher in animals treated with spray dried mixture of RHCL, 
K12 (1:1) compared to animals treated with RHCL. The result 
indicated that the spray drying techniques using different 
hydrophilic carriers like Plasdone K12 would be a promising 
approach to increase rate of dissolution and enhancement 
bioavailability development of solid oral dosage form contains 
poorly water soluble drugs likes raloxifene HCl. 
Acknowledgemnts 
The authors would like to acknowledge International Specialty 
Products Ltd, Hyderabad, INDIA for providing Polyvinyl 
pyrrolidones (Plasdone K12, K29/32 and S-630) and facilities to 
carry out our research work. 
 
Conflict of Interests: The author declare no conflict of 
interests 
 
 
References  
[1]. Kerry JH, Gordon NA, Steven WB, 
Ross AJ, Wayne DL, Neil GP, 
Eugene CR, Cheryl AT, Paul KST, 
Robert EW. Influence of peroxide 
impurities in povidone and 
crospovidone on the stability of 
raloxifene hydrochloride in tablets: 
identification and control of an 
oxidative degradation product. 
Pharm Dev Tech. 2000; 5(3): 303-
308. 
[2]. Delmas PD, Bjarnason N H, Mitlak B, 
Ravoux AC,  Shah A, Huster W, 
Draper M, Christiansen C. Effects of 
Raloxifene on bone mineral density, 
serum cholesterol concentrations, 
and uterine endometrium in 
postmenopausal women. N.Engl. J. 
Med 1997; 337: 1641–1647. 
[3]. Mitlak BH, Cohen FJ. In search of 
optimal long term female hormone 
replacement: the potential of 
selective estrogen receptor 
modulators.Horm Res  1997; 
48:155–163.  
[4]. Garg A, Singh S, Rao VU, Bindu K, 
Balasubramaniam J. Solid State 
Interaction of Raloxifene HCl with 
Different Hydrophilic Carriers during 
Co-grinding and its Effect on 
Dissolution Rate. Drug Dev. Ind. 
Pharm  2009; 35(4): 455-470. 
[5]. Martin  A. 2003  Physical Pharmacy 
fourth ed. Williams and Wilkins 
Baltimore. p.231-240. 
[6]. Patterson  JE, James MB, Forster 
AH, Lancaster RW, Butler JM., 
Rades T. Preparation of glass 
solutions of three poorly water 
soluble drugs by spray drying, melt 
extrusion and ball milling. Int J. 
Pharm. 2007; 336: 22-34.  
[7]. Chaumeil JC. A method of improving 
the bioavailability of poorly soluble 
drugs. Methods Find. Exp. Clin. 
Pharmacol .(1998) 20: 211–215 
[8]. Otsuka M, Kaneniwa N. Effects of 
grinding on the physicochemical 
properties of cephalexin. Chem. 
Pharm. Bull. 1984; 32: 1071–1079. 
[9]. Friedrich H, Nada A, Bodmeier R. 
Solid state and dissolution rate 
characterization of Co-ground 
mixtures of nifedipine and 
hydrophilic carriers. Drug 
Dev.Ind.Pharm. 2005; 31: 719-728. 
[10]. Sugimoto M, Okagaki T, Narisawa 
S, Koide Y, Nakajima K. 
Improvement of dissolution 
characteristics and bioavailability of 
poorly water-soluble drugs by novel 
co-grinding method using water-
soluble polymer. Int. J. Pharm  
1998; 160: 11–19.  
[11]. Suzuki  H, Ogawa M, Hironaka K, 
Ito K , Sunada H. A nifidipine co-
grpund mixture with sodium 
deoxycholate. I. Colloidal particle 
formation and solid state analysis. 
Drug Dev Ind Pharm. 2001; 27 (9): 
943-949. 
[12]. Ahuja N, Katare OP, Singh B. 
Studies on dissolution enhancement 
and mathematical modeling of drug 
release of poorly water-soluble drug 
using water soluble carriers. Eur. J 
Phar. Biopharm.  2007; 65: 26-38. 
[13]. Masters K 2002. Spray drying in 
practice. In: SprayDry Consult 
Rajinikanth et al. International Journal of Drug Delivery 4 (2) 246-256 [2012] 
 
PAGE | 256 | 
 
 
 
International ApS (Eds.), Charlo 
ttenlund, Denmark.  
[14]. Giunchedi P, Conte U. Spray drying 
as a preparation method of 
microparticulate drug delivery 
systems: An overview. S. T. P. 
Pharm. Sci . 1995; 5 : 276-290. 
[15]. Giunchedi P, Conti B,  Genta I, 
Conte U, Puglisi G. Emulsion spray 
drying for the preparation of albumin 
loaded PLGA microspheres. Drug 
Dev. Ind. Pharm. 2001; 27: 745-750. 
[16]. Alanzi FK, El-Badry M,  Ahmed MO, 
Alsarra IA. Spray-dried HPMC 
microparticles of indomethacin: 
impact of drug-polymer ratio and 
viscosity of the polymeric solution on 
dissolution. Sci. Pharm. 2007; 75: 
63-79. 
[17]. Chen R, Tagawa M, Hoshi N, Ogura 
T, Okamoto H, Danjo K. Improved 
dissolution of an insoluble drug 
using a 4-fluid nozzle spray drying 
technique. Chem. Pharm. Bull 2004; 
52: 1066-1070.  
[18]. Filipovic-Grcic  J, Perissutti B, 
Moneghini M, Voinovich D, Martinac 
A, Jalsenjak I. Spray dried 
carbamazepine loaded chitosan and 
HPMC microspheres: preparation 
and characterization. J. Pharm. 
Pharmacol. 2003; 55: 921-931. 
[19]. Moretti MD, Gavini E, Juliano C, 
Pirisino G, Giunchedi P. Spray dried 
microspheres containing ketoprofen 
formulated into capsules and 
tablets. J. Microencapsui. 
2001;18:111-121.  
[20]. Alanzi FK, El-Badry M, Alsarra IA. 
Improvement of Albendazole 
dissolution by preparing 
microparticles using spray-drying 
technique. Saudi Pharm. J. 2006; 
14: 100-107. 
[21]. Balasubramaniam J, Bindu  K, Rao 
VU, Ray D, Haldar R, Brzeczko AW. 
Effect of superdisintegrants on 
dissolution of cationic drugs. Dissol. 
Technol. 2008; May: 18-25.  
[22]. Hancock BC, Zografi G. 
Characteristic and significance of 
the amorphous state in 
pharmaceutical systems. J. Pharm. 
Sci. 1997; 86: 1–12. 
[23]. Williams AC, Timmins P, Lu M,  
forbes RT. Disorder and dissolution 
enhancement: Deposition of 
ibuprofen on to insoluble polymers. 
Eur. J. Pharm. Sci. 2005;  26: 288-
294. 
[24]. Betageri GV, Makarla  KR. 
Enhancement of dissolution of 
glyburide by solid dispersion and 
lyophilization techniques. Int. J. 
Pharm 1995; 126: 155–160. 
[25]. Valizadeh H, Nokhodchi  A, 
Qarakhani N, Zakeri-Milani P, 
Azarmi S, Hassanzadeh D, 
Lobenberg R. Physicochemical 
characterization of solid dispersions 
of indomethacin with PEG 6000, 
Myrj 52, lactose, sorbitol, dextrin, 
and Eudragit® E100. Drug Dev. Ind. 
Pharm 2004; 30: 303–317. 
[26]. Vippangunta  SR, Maul KA, 
Tallavajhala S, Grant  DJW. Solid 
state characterization of nifedipine 
solid dispersion. Int. J. Pharm. 2002; 
236: 111-126. 
[27]. Hancock BC, Parks M. What is true 
solubility advantage for amorphous 
pharmaceuticals?  Pharm Res. 
2000; 17 (4): 397-403. 
 
 
 
 
 
